Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Salgia

Showing results (351-360 of 528) with videos related to

Pageof 53
Sort By:
Scientific Reports|August 25, 2017
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBLYi-Hung Carol Tan, Tamara Mirzapoiazova, Brian M Won, et al.
Journal of Cancer Research and Clinical Oncology|November 16, 2022
Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer riskSam E Wing, Marta M Jankowska, Xiaoke Zou, et al.
Cancer Research|September 23, 2003
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinaseMartin Sattler, Yuri B Pride, Patrick Ma, et al.
Genes, Chromosomes & Cancer|May 16, 2012
Differential expression of RON in small and non-small cell lung cancersRajani Kanteti, Soundararajan Krishnaswamy, Daniel Catenacci, et al.
Cancer Treatment and Research|August 23, 2025
Immunotherapy in Head and Neck CancerBridget E Crossman, Regan L Harmon, Mari Iida, et al.
JCO Precision Oncology|December 12, 2024
Clinical Utility of a Circulating Tumor Cell-Based Cerebrospinal Fluid Assay in the Diagnosis and Molecular Analysis of Leptomeningeal Disease in Patients With Advanced Non-Small Cell Lung CancerJyoti Malhotra, Ramya Muddasani, Jeremy Fricke, et al.
Immunotargets and Therapy|May 3, 2014
Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancerMinu K Srivastava, Li Zhu, Marni Harris-White, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2015
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on ErlotinibPrimo N Lara, Jeff Longmate, Philip C Mack, et al.
Cancer|June 11, 2008
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesotheliomaDavid M Jackman, Hedy L Kindler, Beow Y Yeap, et al.
Journal of Carcinogenesis|December 10, 2013
O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancerRifat Hasina, Mosmi Surati, Ichiro Kawada, et al.
Pageof 53

Showing results (351-360 of 528) with videos related to

Sort By:
Pageof 53
Scientific Reports|August 25, 2017
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBLYi-Hung Carol Tan, Tamara Mirzapoiazova, Brian M Won, et al.
Journal of Cancer Research and Clinical Oncology|November 16, 2022
Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer riskSam E Wing, Marta M Jankowska, Xiaoke Zou, et al.
Cancer Research|September 23, 2003
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinaseMartin Sattler, Yuri B Pride, Patrick Ma, et al.
Genes, Chromosomes & Cancer|May 16, 2012
Differential expression of RON in small and non-small cell lung cancersRajani Kanteti, Soundararajan Krishnaswamy, Daniel Catenacci, et al.
Cancer Treatment and Research|August 23, 2025
Immunotherapy in Head and Neck CancerBridget E Crossman, Regan L Harmon, Mari Iida, et al.
JCO Precision Oncology|December 12, 2024
Clinical Utility of a Circulating Tumor Cell-Based Cerebrospinal Fluid Assay in the Diagnosis and Molecular Analysis of Leptomeningeal Disease in Patients With Advanced Non-Small Cell Lung CancerJyoti Malhotra, Ramya Muddasani, Jeremy Fricke, et al.
Immunotargets and Therapy|May 3, 2014
Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancerMinu K Srivastava, Li Zhu, Marni Harris-White, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2015
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on ErlotinibPrimo N Lara, Jeff Longmate, Philip C Mack, et al.
Cancer|June 11, 2008
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesotheliomaDavid M Jackman, Hedy L Kindler, Beow Y Yeap, et al.
Journal of Carcinogenesis|December 10, 2013
O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancerRifat Hasina, Mosmi Surati, Ichiro Kawada, et al.
Pageof 53